Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) suppresses antigen specific IgG2a and IFN-γ production
- 3 September 2001
- journal article
- research article
- Published by Elsevier BV in Immunology Letters
- Vol. 78 (2), 67-73
- https://doi.org/10.1016/s0165-2478(01)00231-0
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1β and TNF-α secretion following an in vivo lipopolysaccharide challengeLife Sciences, 2000
- Exercise and Neuroendocrine Regulation of Antibody Production: Protective Effect of Physical Activity on Stress-InducedSuppression of the Specific Antibody ResponseInternational Journal of Sports Medicine, 2000
- An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in ratsImmunopharmacology, 2000
- 3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humansNeuroscience & Biobehavioral Reviews, 1999
- 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) administration produces dose-dependent neurochemical, endocrine and immune changes in the ratHuman Psychopharmacology: Clinical and Experimental, 1999
- Acute 3,4-methylenedioxymethamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the ratImmunopharmacology, 1998
- Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ???Ecstasy???)Drug Safety, 1996
- The effect of acute MDMA administration on body temperature, serum corticosterone and neurotransmitter concentrations in male and female ratsHuman Psychopharmacology: Clinical and Experimental, 1995
- Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”)Psychopharmacology, 1995
- Brain corticotropin-releasing hormone- and interleukin-1 beta-induced suppression of specific antibody productionEndocrinology, 1993